After landing a historic FDA OK, Alnylam chief John Maraganore scores a big raise

It took more than 15 years all told, but last year Alnylam $ALNY finally made the big leap into commercializing the first of the RNAi drugs that it had been developing. And CEO John Maraganore and his top team at the bellwether biotech enjoyed a multimillion-dollar windfall on their success.